BIB

Fund Description
ProShares Ultra Nasdaq Biotechnology seeks daily investment results before fees and expenses that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology Index.
Fund Profile
Fund Name ProShares Ultra Nasdaq Biotechnology
Fund Exchange Ticker BIB
Fund Sponsor ProShares
Fund ISIN US74347R2141
Net Expense Ratio 0.95 %
Fund Inception Date 7 April 2010
Fund Legal Structure ETF (Open end fund)
Exchange NASDAQ
Listing Country Code US
Fund Investment Objective
ETF Type Specific Leveraged / Inverse
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Nasdaq Biotech Index
Index Provider Nasdaq
Currency Hedged No
Inverse / Leveraged Leveraged (2x)
Developed / Emerging Developed Market Funds
Market Capitalization Range Broad Market / Multi-Cap
Growth Value Core / Blend
Continent North America
Key Statistics
Return As of Date 22 March 2019
Asset Under Management 231.36 Million (USD)
1 Month Total Return -2.22 %
Year To Date Return 23.62 %
1 Year Total Return -12.11 %
3 Year Annualized Total Return 9.53 %
NAV 51.99
Share Outstanding 4,450,000
Top 10 Holdings (22 March 2019)
Constituent Name Constituent Ticker Constituent Type Weighting
APTINYX INC APTX EQUI
UNUM THERAPEUTICS INC UMRX EQUI
SURFACE ONCOLOGY INC SURF EQUI
ZAFGEN INC ZFGN EQUI
CORIUM INTERNATIONAL INC COMMON STOCK USD CORI EQUI
Net Other Assets / Cash CASH
THERAVANCE BIOPHARMA INC TBPH EQUI
RUBIUS THERAPEUTICS INC RUBY EQUI
MOMENTA PHARMACEUTICALS INC MNTA EQUI
INNOVIVA INC INVA EQUI